首页 > 最新文献

Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery最新文献

英文 中文
Hybrid treatment of type A aortic dissection with a type 2 right-sided aortic arch. A 型主动脉夹层与 2 型右侧主动脉弓的混合治疗。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25115
Elif Coskun Sungur, Emre Demir Benli, Ahmet Sarıtas
{"title":"Hybrid treatment of type A aortic dissection with a type 2 right-sided aortic arch.","authors":"Elif Coskun Sungur, Emre Demir Benli, Ahmet Sarıtas","doi":"10.5606/tgkdc.dergisi.2024.25115","DOIUrl":"10.5606/tgkdc.dergisi.2024.25115","url":null,"abstract":"","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"105-107"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulation strategy with bivalirudin plus aspirin combination during extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome. 在治疗 COVID-19 相关急性呼吸窘迫综合征的体外膜氧合过程中使用双醋瑞定加阿司匹林联合疗法的抗凝策略。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25230
Halide Oğuş, A Ece Altınay, Hakan Hançer, Mustafa Mert Özgür, Mine Şimşek, Şirin Menekşe, Mustafa Emre Gürcü, Mehmet Kaan Kırali

Background: In this study, we present our experience in treating patients receiving extracorporeal membrane oxygenation for novel coronavirus disease-2019 (COVID-19)-associated acute respiratory distress syndrome using a combined anticoagulant and antiaggregant treatment with intravenous infusion of bivalirudin and aspirin.

Methods: Between April 1st, 2020 and January 31st, 2022, a total of 52 adult patients (32 males, 20 females; mean age: 44.5±11.5 years; range, 21 to 71 years) who received extracorporeal membrane oxygenation due to COVID-19-associated acute respiratory distress syndrome and whose anticoagulant treatment consisted of bivalirudin plus aspirin were retrospectively analyzed. During the first 10 days of extracorporeal membrane oxygenation, bivalirudin dosing, activated partial thromboplastin time, and activated clotting time, as well as major bleeding events and patient and/or ECMO-circuit thromboses were recorded.

Results: The mean bivalirudin dose per day ranged from 0.03 to 0.04 mg/kg/h, with a mean overall dose of 0.036 mg/kg/h. The mean activated partial thromboplastin time was 49.1±6.9 sec throughout 10 days of the application. The percentage of time in the target range for activated partial thromboplastin time was 58.9±20.1% within 10 days of application, compared to 33.1±31.1% for the first 24 h. The mean daily activated clotting time was below the target range within the first three days, but it was consistently within the target range after Day 3. During the first 10 days of the application, no mortality occurred. Major bleeding occurred in 11 patients (21.1%) and circuit thrombosis occurred in three patients (5.8%).

Conclusion: In patients receiving extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome, an hourly bivalirudin dose of 0.03 to 0.04 mg/kg/h throughout the first 10 days of application was associated with the targeted anticoagulation profile of 45 to 60 sec. The combination was associated with a comparable rate of major bleeding, but a lower rate of circuit-thrombosis compared to the literature reports.

背景:在本研究中,我们介绍了对接受体外膜氧合治疗的新型冠状病毒病-2019(COVID-19)相关急性呼吸窘迫综合征患者采用静脉输注比伐卢定和阿司匹林联合抗凝和抗聚集治疗的经验:方法: 回顾性分析了2020年4月1日至2022年1月31日期间,因COVID-19相关急性呼吸窘迫综合征而接受体外膜氧合的52例成年患者(男32例,女20例;平均年龄(44.5±11.5)岁;21至71岁),这些患者的抗凝治疗包括比伐卢定和阿司匹林。在体外膜氧合的前 10 天,记录了比伐卢定的剂量、活化部分凝血活酶时间、活化凝血时间以及重大出血事件、患者和/或 ECMO 电路血栓形成:比伐卢定的平均日剂量为 0.03 至 0.04 毫克/千克/小时,平均总剂量为 0.036 毫克/千克/小时。在10天的应用过程中,平均活化部分凝血活酶时间为49.1±6.9秒。用药 10 天内,活化部分凝血活酶时间在目标范围内的时间百分比为 58.9±20.1%,而前 24 小时为 33.1±31.1%。在应用的前 10 天内,没有出现死亡病例。11名患者(21.1%)出现大出血,3名患者(5.8%)出现回路血栓:结论:在接受体外膜氧合治疗 COVID-19 相关急性呼吸窘迫综合征的患者中,在应用的前 10 天中,每小时 0.03 至 0.04 毫克/千克/小时的比伐卢定剂量与 45 至 60 秒的目标抗凝曲线相关。与文献报道相比,该组合的大出血率相当,但回路血栓形成率较低。
{"title":"Anticoagulation strategy with bivalirudin plus aspirin combination during extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome.","authors":"Halide Oğuş, A Ece Altınay, Hakan Hançer, Mustafa Mert Özgür, Mine Şimşek, Şirin Menekşe, Mustafa Emre Gürcü, Mehmet Kaan Kırali","doi":"10.5606/tgkdc.dergisi.2024.25230","DOIUrl":"10.5606/tgkdc.dergisi.2024.25230","url":null,"abstract":"<p><strong>Background: </strong>In this study, we present our experience in treating patients receiving extracorporeal membrane oxygenation for novel coronavirus disease-2019 (COVID-19)-associated acute respiratory distress syndrome using a combined anticoagulant and antiaggregant treatment with intravenous infusion of bivalirudin and aspirin.</p><p><strong>Methods: </strong>Between April 1<sup>st</sup>, 2020 and January 31<sup>st</sup>, 2022, a total of 52 adult patients (32 males, 20 females; mean age: 44.5±11.5 years; range, 21 to 71 years) who received extracorporeal membrane oxygenation due to COVID-19-associated acute respiratory distress syndrome and whose anticoagulant treatment consisted of bivalirudin plus aspirin were retrospectively analyzed. During the first 10 days of extracorporeal membrane oxygenation, bivalirudin dosing, activated partial thromboplastin time, and activated clotting time, as well as major bleeding events and patient and/or ECMO-circuit thromboses were recorded.</p><p><strong>Results: </strong>The mean bivalirudin dose per day ranged from 0.03 to 0.04 mg/kg/h, with a mean overall dose of 0.036 mg/kg/h. The mean activated partial thromboplastin time was 49.1±6.9 sec throughout 10 days of the application. The percentage of time in the target range for activated partial thromboplastin time was 58.9±20.1% within 10 days of application, compared to 33.1±31.1% for the first 24 h. The mean daily activated clotting time was below the target range within the first three days, but it was consistently within the target range after Day 3. During the first 10 days of the application, no mortality occurred. Major bleeding occurred in 11 patients (21.1%) and circuit thrombosis occurred in three patients (5.8%).</p><p><strong>Conclusion: </strong>In patients receiving extracorporeal membrane oxygenation for COVID-19-associated acute respiratory distress syndrome, an hourly bivalirudin dose of 0.03 to 0.04 mg/kg/h throughout the first 10 days of application was associated with the targeted anticoagulation profile of 45 to 60 sec. The combination was associated with a comparable rate of major bleeding, but a lower rate of circuit-thrombosis compared to the literature reports.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"37-45"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management options of valvular heart diseases after heart transplantation: A scoping review. 心脏移植后瓣膜性心脏病的处理方案:范围综述。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25631
Ogulcan Yilmaz, Niamh M Keenan

Background: This study aimed to outline the valvular changes following heart transplantation and describe the management options to address these conditions.

Methods: A literature search using EMBASE, MEDLINE, and PubMed databases was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines in this study. Clinical studies involving patients who had their first heart transplant and articles that mentioned management for valvular heart disease were included. Treatment options were grouped into four categories: cardiac surgery other than retransplant and valve surgery, valve replacement and repairs, nonsurgical interventions, and conservative management.

Results: Nine hundred and three (6.56%) patients out of 13,757 patients (10,529 males, 3,228 females; mean age: 60.3±10.4 years; range, 20 to 83 years) undergoing heart transplantation were identified with valvular disease affecting one or more valves. The mean interval between the transplant and the diagnosis of valve disease was 11.31±6.95 years. The most common valvular heart disease was tricuspid regurgitation, with 796 (94.09%) occurrences, followed by mitral regurgitation (n=22, 2.6%), aortic regurgitation (n=14, 1.65%), aortic stenosis (n=11, 1.3%), and mitral stenosis (n=3, 0.35%). Additionally, the number of surgical valve replacement and repairs (n=89) was higher than nonsurgical interventions (n=20).

Conclusion: Acquired valvular heart diseases after cardiac transplantation are an infrequent clinical presentation that can cause valvular changes in the recipient. According to the extracted data, there is no sole superior management option, and more research is needed in this area.

背景:本研究旨在概述心脏移植术后瓣膜的变化,并描述针对这些情况的处理方案:本研究旨在概述心脏移植术后瓣膜的变化,并描述应对这些情况的管理方案:本研究根据 PRISMA(系统综述和荟萃分析的首选报告项目)指南,使用 EMBASE、MEDLINE 和 PubMed 数据库进行文献检索。本研究纳入了涉及首次心脏移植患者的临床研究以及提及瓣膜性心脏病治疗方法的文章。治疗方案分为四类:再移植和瓣膜手术以外的心脏手术、瓣膜置换和修复、非手术干预和保守治疗:在接受心脏移植手术的13757名患者(男性10529人,女性3228人;平均年龄:60.3±10.4岁;年龄范围:20至83岁)中,有93人(6.56%)被确认患有影响一个或多个瓣膜的瓣膜病。从接受移植手术到确诊瓣膜疾病的平均间隔时间为 11.31±6.95 年。最常见的瓣膜性心脏病是三尖瓣反流,有 796 例(94.09%),其次是二尖瓣反流(22 例,2.6%)、主动脉瓣反流(14 例,1.65%)、主动脉瓣狭窄(11 例,1.3%)和二尖瓣狭窄(3 例,0.35%)。此外,手术瓣膜置换和修复的人数(89 人)高于非手术干预(20 人):结论:心脏移植后获得性瓣膜性心脏病是一种不常见的临床表现,可导致受者瓣膜病变。结论:心脏移植后获得性瓣膜病是一种不常见的临床表现,可导致受者瓣膜病变。根据提取的数据,目前还没有唯一的优越治疗方案,该领域还需要更多的研究。
{"title":"Management options of valvular heart diseases after heart transplantation: A scoping review.","authors":"Ogulcan Yilmaz, Niamh M Keenan","doi":"10.5606/tgkdc.dergisi.2024.25631","DOIUrl":"10.5606/tgkdc.dergisi.2024.25631","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to outline the valvular changes following heart transplantation and describe the management options to address these conditions.</p><p><strong>Methods: </strong>A literature search using EMBASE, MEDLINE, and PubMed databases was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines in this study. Clinical studies involving patients who had their first heart transplant and articles that mentioned management for valvular heart disease were included. Treatment options were grouped into four categories: cardiac surgery other than retransplant and valve surgery, valve replacement and repairs, nonsurgical interventions, and conservative management.</p><p><strong>Results: </strong>Nine hundred and three (6.56%) patients out of 13,757 patients (10,529 males, 3,228 females; mean age: 60.3±10.4 years; range, 20 to 83 years) undergoing heart transplantation were identified with valvular disease affecting one or more valves. The mean interval between the transplant and the diagnosis of valve disease was 11.31±6.95 years. The most common valvular heart disease was tricuspid regurgitation, with 796 (94.09%) occurrences, followed by mitral regurgitation (n=22, 2.6%), aortic regurgitation (n=14, 1.65%), aortic stenosis (n=11, 1.3%), and mitral stenosis (n=3, 0.35%). Additionally, the number of surgical valve replacement and repairs (n=89) was higher than nonsurgical interventions (n=20).</p><p><strong>Conclusion: </strong>Acquired valvular heart diseases after cardiac transplantation are an infrequent clinical presentation that can cause valvular changes in the recipient. According to the extracted data, there is no sole superior management option, and more research is needed in this area.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"112-122"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncological results in primary and secondary malignant chest wall tumors. 原发性和继发性胸壁恶性肿瘤的肿瘤学结果。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25393
Gökhan Kocaman, Yusuf Kahya, Buse Mine Konuk Balcı, Bülent Mustafa Yenigün, Murat Özkan, Hilal Özakıncı, Duru Karasoy, Cabir Yüksel, Serkan Enön, Ayten Kayı Cangır

Background: This study aims to evaluate the oncological results of primary and secondary chest wall tumors treated with curative resections and to investigate possible prognostic factors.

Methods: Between January 2010 and December 2021, a total of 77 patients (53 males, 24 females; median age: 59 years; range, 3 to 87 years) who underwent curative resection for malignant chest wall tumors were retrospectively analyzed. Each tumor was staged according to its histological type. Age, sex, tumor diameter, tumor type (primary/secondary), histological tumor type, grade, stage, complete resection, rib resection, reconstruction, neoadjuvant and adjuvant therapy, recurrence, and survival data were recorded.

Results: Of the chest wall tumors, 33 (42.9%) were primary and 44 (57.1%) were secondary (local invasion, metastasis). Nine (11.7%) patients had positive surgical margins. Chest wall resection was most commonly performed due to lung cancer invasion (46.8%), followed by Ewing sarcoma (13%). Recurrence was observed in 34 (44.2%) patients. The five-year recurrence-free survival rate was 42.7% and the five-year overall survival rate was 58.6%. There was no significant difference between the primary and secondary tumors in terms of recurrence-free and overall survival (p=0.663 and p=0.313, respectively). In the multivariate analysis, tumor grade and rib resection were found to be independent prognostic factors for both recurrence-free survival (p=0.005 and p<0.001, respectively) and overall survival (p=0.048 and p=0.007, respectively).

Conclusion: Successful oncological results can be achieved in wellselected patients with primary and secondary chest wall tumors. The grade of the tumor should be taken into account while determining the neoadjuvant or adjuvant treatment approach and surgical margin width. Rib resection should not be avoided when necessary.

背景:本研究旨在评估接受根治性切除术治疗的原发性和继发性胸壁肿瘤的肿瘤学结果,并探讨可能的预后因素:本研究旨在评估接受根治性切除术治疗的原发性和继发性胸壁肿瘤的肿瘤学结果,并探讨可能的预后因素:方法:回顾性分析了 2010 年 1 月至 2021 年 12 月期间,接受胸壁恶性肿瘤根治性切除术的 77 例患者(男 53 例,女 24 例;中位年龄:59 岁;范围:3 至 87 岁)。每个肿瘤都根据其组织学类型进行了分期。记录了年龄、性别、肿瘤直径、肿瘤类型(原发性/继发性)、组织学肿瘤类型、分级、分期、完全切除、肋骨切除、重建、新辅助治疗和辅助治疗、复发和生存数据:在胸壁肿瘤中,33 例(42.9%)为原发性,44 例(57.1%)为继发性(局部浸润、转移)。9例(11.7%)患者的手术切缘呈阳性。胸壁切除术最常见的原因是肺癌侵犯(46.8%),其次是尤文肉瘤(13%)。34例(44.2%)患者出现复发。五年无复发生存率为42.7%,五年总生存率为58.6%。在无复发生存率和总生存率方面,原发性肿瘤和继发性肿瘤之间没有明显差异(分别为P=0.663和P=0.313)。多变量分析发现,肿瘤分级和肋骨切除是无复发生存率的独立预后因素(P=0.005 和 P=0.313):经过精心挑选的原发性和继发性胸壁肿瘤患者可以获得成功的肿瘤治疗效果。在确定新辅助或辅助治疗方法和手术边缘宽度时,应考虑肿瘤的分级。必要时不应避免肋骨切除。
{"title":"Oncological results in primary and secondary malignant chest wall tumors.","authors":"Gökhan Kocaman, Yusuf Kahya, Buse Mine Konuk Balcı, Bülent Mustafa Yenigün, Murat Özkan, Hilal Özakıncı, Duru Karasoy, Cabir Yüksel, Serkan Enön, Ayten Kayı Cangır","doi":"10.5606/tgkdc.dergisi.2024.25393","DOIUrl":"10.5606/tgkdc.dergisi.2024.25393","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the oncological results of primary and secondary chest wall tumors treated with curative resections and to investigate possible prognostic factors.</p><p><strong>Methods: </strong>Between January 2010 and December 2021, a total of 77 patients (53 males, 24 females; median age: 59 years; range, 3 to 87 years) who underwent curative resection for malignant chest wall tumors were retrospectively analyzed. Each tumor was staged according to its histological type. Age, sex, tumor diameter, tumor type (primary/secondary), histological tumor type, grade, stage, complete resection, rib resection, reconstruction, neoadjuvant and adjuvant therapy, recurrence, and survival data were recorded.</p><p><strong>Results: </strong>Of the chest wall tumors, 33 (42.9%) were primary and 44 (57.1%) were secondary (local invasion, metastasis). Nine (11.7%) patients had positive surgical margins. Chest wall resection was most commonly performed due to lung cancer invasion (46.8%), followed by Ewing sarcoma (13%). Recurrence was observed in 34 (44.2%) patients. The five-year recurrence-free survival rate was 42.7% and the five-year overall survival rate was 58.6%. There was no significant difference between the primary and secondary tumors in terms of recurrence-free and overall survival (p=0.663 and p=0.313, respectively). In the multivariate analysis, tumor grade and rib resection were found to be independent prognostic factors for both recurrence-free survival (p=0.005 and p<0.001, respectively) and overall survival (p=0.048 and p=0.007, respectively).</p><p><strong>Conclusion: </strong>Successful oncological results can be achieved in wellselected patients with primary and secondary chest wall tumors. The grade of the tumor should be taken into account while determining the neoadjuvant or adjuvant treatment approach and surgical margin width. Rib resection should not be avoided when necessary.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"55-61"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of the effects of different drugs on the prevention of intrapleural adhesion in a rat model. 在大鼠模型中研究不同药物对预防胸膜内粘连的影响。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25516
Barış Sarıçoban, Murat Kuru, Sıddıka Fındık, İbrahim Kılınç, Tamer Altınok

Background: The aim of this study was to investigate the antifibrinolytic and anti-inflammatory effects of hesperidin, tenoxicam and enoxaparin on intrapleural adhesions in an experimental rat model.

Methods: A total of 52 healthy adult male Wistar Albino rats from the same colony were randomly divided into six groups as sham (Group 1), surgical control (Group 2), low-dose hesperidin (Group 3), high-dose hesperidin (Group 4), tenoxicam (Group 5), and enoxaparin (Group 6). All subjects underwent left thoracotomy and except for the sham group, an adhesion model was applied and, postoperatively, the drugs were administered intraperitoneally. On Day 11 postoperatively, the rats were sacrificed and their blood levels of interleukin-1β and interleukin-10 were examined and they were evaluated for pleural adhesion area, adhesion severity score, mesothelial cell proliferation score, mononuclear cell infiltration score, and macrophage infiltration score in the collagen layer.

Results: The lowest adhesion area and adhesion severity score were found in Group 6. There was a statistically significant difference between Group 2 and Group 6 and between Group 3 and Group 6 in terms of both parameters (p=0.04 and p=0.02). As for adhesion area, a statistically significant difference was found between Group 5 and Group 6 (p=0.04). Statistically significant differences were also found between Group 2 and Group 5 in terms of mesothelial cell proliferation scores and between Group 1 and Group 4 in terms of mononuclear cell infiltration scores (p=0.03 and p=0.02).

Conclusion: Enoxaparin, tenoxicam, and high-dose hesperidin act at different points to prevent adhesion in rats.

背景:本研究旨在探讨七叶皂苷、替诺昔康和依诺肝素对实验大鼠胸膜内粘连的抗纤维蛋白溶解和抗炎作用:将来自同一鼠群的 52 只健康成年雄性 Wistar Albino 大鼠随机分为 6 组,即假组(第 1 组)、手术对照组(第 2 组)、低剂量橙皮素组(第 3 组)、高剂量橙皮素组(第 4 组)、替诺昔康组(第 5 组)和依诺肝素组(第 6 组)。除假组外,所有受试者均接受了左侧开胸手术,并应用粘连模型,术后腹腔注射药物。术后第 11 天,大鼠被处死,检测其血液中白细胞介素-1β 和白细胞介素-10 的水平,并评估胸膜粘连面积、粘连严重程度评分、间皮细胞增殖评分、单核细胞浸润评分和胶原层巨噬细胞浸润评分:第 6 组的粘连面积和粘连严重程度评分最低,第 2 组和第 6 组之间以及第 3 组和第 6 组之间在这两项参数上的差异均有统计学意义(P=0.04 和 P=0.02)。至于粘附面积,第 5 组和第 6 组之间的差异有统计学意义(P=0.04)。在间皮细胞增殖评分方面,第 2 组和第 5 组之间的差异也有统计学意义;在单核细胞浸润评分方面,第 1 组和第 4 组之间的差异也有统计学意义(P=0.03 和 P=0.02):结论:依诺肝素、替诺昔康和大剂量七叶皂苷能在不同点上防止大鼠粘连。
{"title":"Investigation of the effects of different drugs on the prevention of intrapleural adhesion in a rat model.","authors":"Barış Sarıçoban, Murat Kuru, Sıddıka Fındık, İbrahim Kılınç, Tamer Altınok","doi":"10.5606/tgkdc.dergisi.2024.25516","DOIUrl":"10.5606/tgkdc.dergisi.2024.25516","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to investigate the antifibrinolytic and anti-inflammatory effects of hesperidin, tenoxicam and enoxaparin on intrapleural adhesions in an experimental rat model.</p><p><strong>Methods: </strong>A total of 52 healthy adult male Wistar Albino rats from the same colony were randomly divided into six groups as sham (Group 1), surgical control (Group 2), low-dose hesperidin (Group 3), high-dose hesperidin (Group 4), tenoxicam (Group 5), and enoxaparin (Group 6). All subjects underwent left thoracotomy and except for the sham group, an adhesion model was applied and, postoperatively, the drugs were administered intraperitoneally. On Day 11 postoperatively, the rats were sacrificed and their blood levels of interleukin-1β and interleukin-10 were examined and they were evaluated for pleural adhesion area, adhesion severity score, mesothelial cell proliferation score, mononuclear cell infiltration score, and macrophage infiltration score in the collagen layer.</p><p><strong>Results: </strong>The lowest adhesion area and adhesion severity score were found in Group 6. There was a statistically significant difference between Group 2 and Group 6 and between Group 3 and Group 6 in terms of both parameters (p=0.04 and p=0.02). As for adhesion area, a statistically significant difference was found between Group 5 and Group 6 (p=0.04). Statistically significant differences were also found between Group 2 and Group 5 in terms of mesothelial cell proliferation scores and between Group 1 and Group 4 in terms of mononuclear cell infiltration scores (p=0.03 and p=0.02).</p><p><strong>Conclusion: </strong>Enoxaparin, tenoxicam, and high-dose hesperidin act at different points to prevent adhesion in rats.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"62-68"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative pulmonary complications in awake video-assisted thoracoscopic surgery: Our 10-year experience. 清醒状态下视频辅助胸腔镜手术的术后肺部并发症:我们的十年经验
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25478
Özlem Turhan, Nükhet Sivrikoz, Salih Duman, Murat Kara, Zerrin Sungur

Background: The aim of this study was to evaluate the effect of awake video-assisted thoracoscopic surgery on postoperative pulmonary complications among patients with different risk scores using the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT).

Methods: Between January 2011 and August 2021, a total of 246 patients (158 males, 88 females; mean age: 59.1±13.6 years; range, 25 to 84 years) who underwent awake video-assisted thoracoscopic surgery were retrospectively analyzed. According to the ARISCAT scores, the patients with low and intermediate scores were included in Group L (n=173), while those with high scores (n=73) were included in Group H. Sedation protocol consisted of the combination of midazolam and fentanyl with propofol infusion, if necessary. Oxygen was delivered via face mask or nasal canula (2 to 5 L/min) maintaining an oxygen saturation of >95%, and analgesia was achieved with intercostal nerve block. Demographics, operative, and postoperative data of the patients, and pulmonary complications were evaluated.

Results: Demographics, operative, and postoperative data were similar between the groups. Postoperative pulmonary complications were observed in 20 (27%) patients in Group H and 29 (17%) patients in Group L without statistically significant difference (p=0.056). Surgical approaches consisted of pleural procedures (n=194) and pulmonary resection (n=52). The incidence of pulmonary complications was significantly higher in the pulmonary resection compared to non-pulmonary procedures (p=0.027).

Conclusion: Awake video-assisted thoracoscopic surgery seems to be beneficial in reducing the incidence of postoperative pulmonary complications in high-risk patients as assessed with the ARISCAT.

背景:本研究的目的是利用加泰罗尼亚外科患者呼吸风险评估(ARISCAT)评估清醒视频辅助胸腔镜手术对不同风险评分患者术后肺部并发症的影响:方法: 对 2011 年 1 月至 2021 年 8 月期间接受清醒视频辅助胸腔镜手术的 246 例患者(男 158 例,女 88 例;平均年龄:59.1±13.6 岁;范围:25 至 84 岁)进行了回顾性分析。根据ARISCAT评分,低分和中分患者被纳入L组(173人),高分患者(73人)被纳入H组。镇静方案包括咪达唑仑和芬太尼联合使用,必要时注入异丙酚。通过面罩或鼻导管输氧(2 至 5 升/分钟),保持血氧饱和度大于 95%,并通过肋间神经阻滞实现镇痛。对患者的人口统计学、手术和术后数据以及肺部并发症进行了评估:结果:两组患者的人口统计学、手术和术后数据相似。H组有20例(27%)患者出现术后肺部并发症,L组有29例(17%)患者出现术后肺部并发症,两组患者术后肺部并发症无统计学差异(P=0.056)。手术方法包括胸膜手术(194 人)和肺切除术(52 人)。肺切除术的肺部并发症发生率明显高于非肺部手术(P=0.027):结论:根据 ARISCAT 评估,清醒状态下的视频辅助胸腔镜手术似乎有利于降低高危患者术后肺部并发症的发生率。
{"title":"Postoperative pulmonary complications in awake video-assisted thoracoscopic surgery: Our 10-year experience.","authors":"Özlem Turhan, Nükhet Sivrikoz, Salih Duman, Murat Kara, Zerrin Sungur","doi":"10.5606/tgkdc.dergisi.2024.25478","DOIUrl":"10.5606/tgkdc.dergisi.2024.25478","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the effect of awake video-assisted thoracoscopic surgery on postoperative pulmonary complications among patients with different risk scores using the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT).</p><p><strong>Methods: </strong>Between January 2011 and August 2021, a total of 246 patients (158 males, 88 females; mean age: 59.1±13.6 years; range, 25 to 84 years) who underwent awake video-assisted thoracoscopic surgery were retrospectively analyzed. According to the ARISCAT scores, the patients with low and intermediate scores were included in Group L (n=173), while those with high scores (n=73) were included in Group H. Sedation protocol consisted of the combination of midazolam and fentanyl with propofol infusion, if necessary. Oxygen was delivered via face mask or nasal canula (2 to 5 L/min) maintaining an oxygen saturation of >95%, and analgesia was achieved with intercostal nerve block. Demographics, operative, and postoperative data of the patients, and pulmonary complications were evaluated.</p><p><strong>Results: </strong>Demographics, operative, and postoperative data were similar between the groups. Postoperative pulmonary complications were observed in 20 (27%) patients in Group H and 29 (17%) patients in Group L without statistically significant difference (p=0.056). Surgical approaches consisted of pleural procedures (n=194) and pulmonary resection (n=52). The incidence of pulmonary complications was significantly higher in the pulmonary resection compared to non-pulmonary procedures (p=0.027).</p><p><strong>Conclusion: </strong>Awake video-assisted thoracoscopic surgery seems to be beneficial in reducing the incidence of postoperative pulmonary complications in high-risk patients as assessed with the ARISCAT.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"75-83"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prognostic significance of PD-1 and its ligands in non-small cell lung cancer. PD-1 及其配体在非小细胞肺癌中的预后意义。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25394
Ozan Usluer, Özde Elif Gökbayrak, Aylin Erol, Tekincan Çağrı Aktaş, Güntuğ Batıhan, Şeyda Örs Kaya, Ahmet Üçvet, Zekiye Aydoğdu, Zekiye Altun, İlhan Öztop, Safiye Aktaş

Background: In this study, we aimed to investigate the prognostic value of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and programmed cell death ligand 2 (PD-L2) expressions on immune and cancer cells in terms of survival in patients with lung adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Methods: Between January 2000 and December 2012, a total of 191 patients (172 males, 19 females; mean age: 60.3±8.4 years; range, 38 to 78 years) who were diagnosed with non-small cell lung cancer and underwent anatomic resection and mediastinal lymph node dissection were retrospectively analyzed. The patients were evaluated in three groups including lung squamous cell carcinoma (n=61), adenocarcinoma (n=66), and large-cell carcinoma (n=64). The survival rates of all three groups were compared in terms of immunohistochemical expression levels of PD-1, PD-L1, and PD-L2.

Results: The mean follow-up was 71.8±47.9 months. In all histological subtypes, PD-1 expressions on tumor and immune cells were observed in 33% (61/191) and in 53.1% (102/191) of the patients, respectively. Higher expression levels of PD-L1 and PD-L2 at any intensity on tumor and immune cells were defined only in lung adenocarcinomas, and PD-L1 and PD-L2 values were detected in 36.4% (22/64) of these patients. The PD-L1 expressions on tumor and immune cells were observed in 41.7% (10/24) and 25% (6/24) of the patients, respectively. The PD-L2 expressions on tumor and immune cells were detected in 16.7% (4/24) and 8.4% (2/24) of the patients, respectively. Univariate and multivariate analyses revealed that PD-1 expression in tumor cells was an independent prognostic factor in all histological subtypes.

Conclusion: Our study results suggest that PD-1 expression is a poor prognostic factor for overall survival in patients with completely resected adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

研究背景本研究旨在探讨免疫细胞和癌细胞上程序性细胞死亡蛋白1(PD-1)、程序性细胞死亡配体1(PD-L1)和程序性细胞死亡配体2(PD-L2)的表达对肺腺癌、鳞癌和大细胞癌患者生存期的预后价值:回顾性分析2000年1月至2012年12月期间确诊为非小细胞肺癌并接受解剖切除术和纵隔淋巴结清扫术的191例患者(男172例,女19例;平均年龄:60.3±8.4岁;范围:38至78岁)。患者分为三组,包括肺鳞癌(61 人)、腺癌(66 人)和大细胞癌(64 人)。根据 PD-1、PD-L1 和 PD-L2 的免疫组化表达水平比较了三组患者的生存率:结果:平均随访时间为(71.8±47.9)个月。在所有组织学亚型中,分别有33%(61/191)和53.1%(102/191)的患者观察到肿瘤细胞和免疫细胞上的PD-1表达。PD-L1和PD-L2在肿瘤细胞和免疫细胞上任何强度的较高表达水平仅见于肺腺癌,这些患者中有36.4%(22/64)检测到PD-L1和PD-L2值。41.7%的患者(10/24)和25%的患者(6/24)在肿瘤细胞和免疫细胞上观察到了PD-L1表达。16.7%(4/24)和8.4%(2/24)的患者在肿瘤细胞和免疫细胞上检测到PD-L2表达。单变量和多变量分析显示,在所有组织学亚型中,肿瘤细胞中的PD-1表达是一个独立的预后因素:我们的研究结果表明,PD-1表达是完全切除腺癌、鳞癌和大细胞癌患者总生存率的不良预后因素。
{"title":"The prognostic significance of PD-1 and its ligands in non-small cell lung cancer.","authors":"Ozan Usluer, Özde Elif Gökbayrak, Aylin Erol, Tekincan Çağrı Aktaş, Güntuğ Batıhan, Şeyda Örs Kaya, Ahmet Üçvet, Zekiye Aydoğdu, Zekiye Altun, İlhan Öztop, Safiye Aktaş","doi":"10.5606/tgkdc.dergisi.2024.25394","DOIUrl":"10.5606/tgkdc.dergisi.2024.25394","url":null,"abstract":"<p><strong>Background: </strong>In this study, we aimed to investigate the prognostic value of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and programmed cell death ligand 2 (PD-L2) expressions on immune and cancer cells in terms of survival in patients with lung adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.</p><p><strong>Methods: </strong>Between January 2000 and December 2012, a total of 191 patients (172 males, 19 females; mean age: 60.3±8.4 years; range, 38 to 78 years) who were diagnosed with non-small cell lung cancer and underwent anatomic resection and mediastinal lymph node dissection were retrospectively analyzed. The patients were evaluated in three groups including lung squamous cell carcinoma (n=61), adenocarcinoma (n=66), and large-cell carcinoma (n=64). The survival rates of all three groups were compared in terms of immunohistochemical expression levels of PD-1, PD-L1, and PD-L2.</p><p><strong>Results: </strong>The mean follow-up was 71.8±47.9 months. In all histological subtypes, PD-1 expressions on tumor and immune cells were observed in 33% (61/191) and in 53.1% (102/191) of the patients, respectively. Higher expression levels of PD-L1 and PD-L2 at any intensity on tumor and immune cells were defined only in lung adenocarcinomas, and PD-L1 and PD-L2 values were detected in 36.4% (22/64) of these patients. The PD-L1 expressions on tumor and immune cells were observed in 41.7% (10/24) and 25% (6/24) of the patients, respectively. The PD-L2 expressions on tumor and immune cells were detected in 16.7% (4/24) and 8.4% (2/24) of the patients, respectively. Univariate and multivariate analyses revealed that PD-1 expression in tumor cells was an independent prognostic factor in all histological subtypes.</p><p><strong>Conclusion: </strong>Our study results suggest that PD-1 expression is a poor prognostic factor for overall survival in patients with completely resected adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"84-92"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of preoperative scores on postoperative process in bronchiectasis surgery. 术前评分对支气管扩张手术术后过程的影响。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2023.25290
Ali Murat Akçıl, Onur Volkan Yaran, Levent Cansever, Cemal Aker, Yunus Seyrek, Mehmet Ali Bedirhan

Background: In this study, we aimed to investigate the relationship between bronchiectasis criteria, scores, and indices used today and surgical interventions due to bronchiectasis.

Methods: Between January 2009 and December 2018, a total of 106 patients (53 males, 53 females; mean age: 39.1±12.3 years; range, 14 to 68 years) with non-cystic fibrous bronchiectasis were retrospectively analyzed. We determined symptom improvement and complications as main factors. We divided the patients into two main groups: those who had symptom improvement after pulmonary resection (Group 1, n=89) and those who did not (Group 2, n=17). We further analyzed patients who had postoperative complications (n=27) with those who did not (n=79). The following scores and criteria were used in this study: modified Reiff score, Gudbjerg criteria, Naidich criteria, Bronchiectasis Severity Index, and FACED scoring.

Results: There was a statistically significant difference between the groups in terms of the modified Reiff scores and FACED scores. As the modified Reiff score increased, there was a higher rate of symptom relief (p=0.04). Contrary to this, an increase in the FACED score predicted a poorer postoperative outcome (p=0.03). Considering complications, a significant difference was observed in the Gudjberg criteria, and higher grade suggested a higher risk of complication (p=0.02).

Conclusion: The grading and scoring systems related to bronchiectasis may have some predictive value in terms of surgical outcomes. A high modified Reiff score and a low FACED score can predict postoperative success, whereas Gudbjerg criteria can indicate postoperative complications.

背景:本研究旨在探讨支气管扩张症标准、评分和指数与支气管扩张症手术干预之间的关系:在这项研究中,我们旨在调查支气管扩张症的标准、评分和目前使用的指数与支气管扩张症导致的手术干预之间的关系:2009年1月至2018年12月期间,我们对106例非囊性纤维性支气管扩张症患者(男53例,女53例;平均年龄:39.1±12.3岁;范围:14至68岁)进行了回顾性分析。我们将症状改善和并发症作为主要因素。我们将患者分为两大组:肺切除术后症状改善的患者(第一组,人数=89)和症状未改善的患者(第二组,人数=17)。我们进一步分析了术后出现并发症的患者(27 人)和未出现并发症的患者(79 人)。本研究采用了以下评分和标准:改良雷夫评分、古比耶格标准、奈迪希标准、支气管扩张症严重程度指数和 FACED 评分:结果:在改良雷夫评分和 FACED 评分方面,各组之间存在显著的统计学差异。随着改良雷夫评分的增加,症状缓解率较高(P=0.04)。与此相反,FACED 评分的增加预示着术后效果较差(P=0.03)。在并发症方面,Gudjberg 标准有显著差异,等级越高,并发症风险越高(P=0.02):结论:与支气管扩张相关的分级和评分系统可能对手术结果有一定的预测价值。结论:与支气管扩张相关的分级和评分系统可能对手术结果有一定的预测价值。改良 Reiff 评分高和 FACED 评分低可预测术后成功率,而 Gudbjerg 标准可提示术后并发症。
{"title":"Impact of preoperative scores on postoperative process in bronchiectasis surgery.","authors":"Ali Murat Akçıl, Onur Volkan Yaran, Levent Cansever, Cemal Aker, Yunus Seyrek, Mehmet Ali Bedirhan","doi":"10.5606/tgkdc.dergisi.2023.25290","DOIUrl":"10.5606/tgkdc.dergisi.2023.25290","url":null,"abstract":"<p><strong>Background: </strong>In this study, we aimed to investigate the relationship between bronchiectasis criteria, scores, and indices used today and surgical interventions due to bronchiectasis.</p><p><strong>Methods: </strong>Between January 2009 and December 2018, a total of 106 patients (53 males, 53 females; mean age: 39.1±12.3 years; range, 14 to 68 years) with non-cystic fibrous bronchiectasis were retrospectively analyzed. We determined symptom improvement and complications as main factors. We divided the patients into two main groups: those who had symptom improvement after pulmonary resection (Group 1, n=89) and those who did not (Group 2, n=17). We further analyzed patients who had postoperative complications (n=27) with those who did not (n=79). The following scores and criteria were used in this study: modified Reiff score, Gudbjerg criteria, Naidich criteria, Bronchiectasis Severity Index, and FACED scoring.</p><p><strong>Results: </strong>There was a statistically significant difference between the groups in terms of the modified Reiff scores and FACED scores. As the modified Reiff score increased, there was a higher rate of symptom relief (p=0.04). Contrary to this, an increase in the FACED score predicted a poorer postoperative outcome (p=0.03). Considering complications, a significant difference was observed in the Gudjberg criteria, and higher grade suggested a higher risk of complication (p=0.02).</p><p><strong>Conclusion: </strong>The grading and scoring systems related to bronchiectasis may have some predictive value in terms of surgical outcomes. A high modified Reiff score and a low FACED score can predict postoperative success, whereas Gudbjerg criteria can indicate postoperative complications.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"46-54"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute kidney injury after surgical treatment of failed endovascular aneurysm repair. 血管内动脉瘤修复手术失败后的急性肾损伤。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25082
Ünal Aydın, Zihni Mert Duman, Muhammed Bayram, Emre Yaşar, Ersin Kadiroğulları, Ali Kemal Arslan, Sefa Eltutan, Muhammed Onur Hanedan

Background: This study aims to report the incidence of acute kidney injury following surgical reconstruction after a failed endovascular aneurysm repair (EVAR) in patients with abdominal aortic aneurysms.

Methods: This retrospective study included 44 patients (39 males, 5 females; mean age: 70±11.3 years; range, 35 to 84 years) who underwent emergency or elective surgical reconstruction after failed EVAR between February 2015 and January 2019. Patients were divided into two groups: acute kidney injury group and no acute kidney injury group. The primary end-point of the study was to evaluate the development of acute kidney injury following surgery. The secondary end-points included the 30-day and one-year mortality rates.

Results: Surgical reconstruction of the abdominal aorta was performed electively in 29 (65.9%) patients and urgently in 15 (34.1%) patients. Acute kidney injury occurred in 12 (27.3%) patients. The interval from endovascular aneurysm repair to surgical reconstruction was statistically significantly higher in the no acute kidney injury group than in the acute kidney injury group (24.6±11.5 and 18.1±13.3 months, respectively; p=0.145). The mean abdominal aortic aneurysm diameter, neck angulation, and neck diameter were statistically significantly higher in the acute kidney injury group than in the no acute kidney injury group (p=0.001, p=0.009, and p<0.001, respectively). No statistically significant difference was observed between the acute kidney injury and no acute kidney injury groups for the overall 30-day mortality (p=0.185) and oneyear mortality (p=0.999).

Conclusion: Acute kidney injury is not uncommon after the surgical reconstruction of a failed EVAR. Aneurysm-related anatomical factors may have an impact on the development of postoperative acute kidney injury. Comprehensive surgical planning should be performed for open abdominal aortic surgery after a failed EVAR.

背景:本研究旨在报告腹主动脉瘤患者血管内动脉瘤修补术(EVAR)失败后进行手术重建时急性肾损伤的发生率:本研究旨在报告腹主动脉瘤患者血管内动脉瘤修补术(EVAR)失败后进行手术重建后急性肾损伤的发生率:这项回顾性研究纳入了2015年2月至2019年1月期间接受EVAR失败后急诊或择期手术重建的44名患者(39名男性,5名女性;平均年龄:70±11.3岁;范围:35岁至84岁)。患者分为两组:急性肾损伤组和无急性肾损伤组。研究的主要终点是评估术后急性肾损伤的发生情况。次要终点包括30天和一年的死亡率:29例(65.9%)患者选择了腹主动脉重建手术,15例(34.1%)患者选择了急诊手术。12例(27.3%)患者出现急性肾损伤。从血管内动脉瘤修复到手术重建的间隔时间,无急性肾损伤组明显高于急性肾损伤组(分别为 24.6±11.5 个月和 18.1±13.3 个月;P=0.145)。急性肾损伤组的腹主动脉瘤平均直径、颈部角度和颈部直径均明显高于无急性肾损伤组,差异有统计学意义(P=0.001、P=0.009 和 P=0.145):EVAR失败手术重建后急性肾损伤并不少见。动脉瘤相关的解剖因素可能会影响术后急性肾损伤的发生。在 EVAR 失败后进行开放式腹主动脉手术时应进行全面的手术规划。
{"title":"Acute kidney injury after surgical treatment of failed endovascular aneurysm repair.","authors":"Ünal Aydın, Zihni Mert Duman, Muhammed Bayram, Emre Yaşar, Ersin Kadiroğulları, Ali Kemal Arslan, Sefa Eltutan, Muhammed Onur Hanedan","doi":"10.5606/tgkdc.dergisi.2024.25082","DOIUrl":"10.5606/tgkdc.dergisi.2024.25082","url":null,"abstract":"<p><strong>Background: </strong>This study aims to report the incidence of acute kidney injury following surgical reconstruction after a failed endovascular aneurysm repair (EVAR) in patients with abdominal aortic aneurysms.</p><p><strong>Methods: </strong>This retrospective study included 44 patients (39 males, 5 females; mean age: 70±11.3 years; range, 35 to 84 years) who underwent emergency or elective surgical reconstruction after failed EVAR between February 2015 and January 2019. Patients were divided into two groups: acute kidney injury group and no acute kidney injury group. The primary end-point of the study was to evaluate the development of acute kidney injury following surgery. The secondary end-points included the 30-day and one-year mortality rates.</p><p><strong>Results: </strong>Surgical reconstruction of the abdominal aorta was performed electively in 29 (65.9%) patients and urgently in 15 (34.1%) patients. Acute kidney injury occurred in 12 (27.3%) patients. The interval from endovascular aneurysm repair to surgical reconstruction was statistically significantly higher in the no acute kidney injury group than in the acute kidney injury group (24.6±11.5 and 18.1±13.3 months, respectively; p=0.145). The mean abdominal aortic aneurysm diameter, neck angulation, and neck diameter were statistically significantly higher in the acute kidney injury group than in the no acute kidney injury group (p=0.001, p=0.009, and p<0.001, respectively). No statistically significant difference was observed between the acute kidney injury and no acute kidney injury groups for the overall 30-day mortality (p=0.185) and oneyear mortality (p=0.999).</p><p><strong>Conclusion: </strong>Acute kidney injury is not uncommon after the surgical reconstruction of a failed EVAR. Aneurysm-related anatomical factors may have an impact on the development of postoperative acute kidney injury. Comprehensive surgical planning should be performed for open abdominal aortic surgery after a failed EVAR.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"17-25"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cough-induced rib fractures: A comprehensive analysis of 90 patients in a single center. 咳嗽引起的肋骨骨折:对一个中心 90 名患者的综合分析。
IF 0.6 4区 医学 Q4 SURGERY Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.5606/tgkdc.dergisi.2024.25655
Mehmet Oğuzhan Özyurtkan, Zeliha Arslan Ulukan, Uğur Temel

Background: This study aims to evaluate clinical and radiological characteristics of the patients with cough-induced rib fractures.

Methods: Between January 2008 and December 2022, a total of 90 patients (35 males, 55 females; mean age: 58±20 years; range, 20 to 92 years) who had cough-induced rib fractures were retrospectively analyzed. Patients' characteristics, findings of physical and radiological examination, and patients' outcomes were recorded.

Results: Of the patients, 64% were postmenopausal, 37% had metabolic disease of the bone, and 21% had chronic cough. Cough etiology was acute upper respiratory tract infection (32%), followed by chronic obstructive pulmonary disease. Thoracic computed tomography documented 154 fractures. Cough-induced rib fractures were mostly on the right side (58%). Multiple fractures were more commonly seen in older patients (p=0.007), in the presence of novel coronavirus disease-2019 (COVID-19) pneumonia (p=0.03), and metabolic disease of the bone (p=0.01). Mostly the sixth rib was affected (23%). Most fractures (81.3%) affected the fourth to ninth ribs. Most fractures developed on the anterolateral aspect of the rib (51%). The mean duration of hospital stay was 5.0±1.6 days. Morbidity developed in one patient (1.1%) (hemothorax). Mortality occurred in two patients (2.2%) due to COVID-19 pneumonia and acute myocardial infarction.

Conclusion: Localized pain after cough should be investigated in terms of cough-induced rib fractures. Cough-induced rib fractures are mostly seen in the presence of acute upper respiratory tract infection, chronic obstructive pulmonary disease, and pneumonia. Postmenopausal women are more risky to develop cough-induced rib fractures. Multiple cough-induced rib fractures are common in the presence of metabolic disease of the bone, older age, COVID-19 pneumonia.

背景:本研究旨在评估咳嗽诱发肋骨骨折患者的临床和放射学特征:本研究旨在评估咳嗽诱发肋骨骨折患者的临床和放射学特征:方法:回顾性分析 2008 年 1 月至 2022 年 12 月期间咳嗽诱发肋骨骨折的 90 例患者(男 35 例,女 55 例;平均年龄:58±20 岁;年龄范围:20 至 92 岁)。记录了患者的特征、体格检查和放射学检查结果以及患者的预后:结果:64%的患者已绝经,37%患有骨代谢疾病,21%患有慢性咳嗽。咳嗽病因是急性上呼吸道感染(32%),其次是慢性阻塞性肺病。胸部计算机断层扫描记录了154处骨折。咳嗽引起的肋骨骨折主要发生在右侧(58%)。多发性骨折多见于年龄较大的患者(P=0.007)、新型冠状病毒病-2019(COVID-19)肺炎患者(P=0.03)和骨代谢疾病患者(P=0.01)。大多数患者的第六根肋骨受到影响(23%)。大多数骨折(81.3%)发生在第四至第九根肋骨。大多数骨折发生在肋骨的前外侧(51%)。平均住院时间为 5.0±1.6 天。一名患者(1.1%)发病(血胸)。两名患者(2.2%)因COVID-19肺炎和急性心肌梗死死亡:结论:咳嗽后的局部疼痛应从咳嗽诱发肋骨骨折的角度进行研究。咳嗽诱发肋骨骨折多见于急性上呼吸道感染、慢性阻塞性肺病和肺炎。绝经后的女性更容易发生咳嗽诱发的肋骨骨折。多发性咳嗽诱发的肋骨骨折常见于骨代谢疾病、老年人和 COVID-19 肺炎。
{"title":"Cough-induced rib fractures: A comprehensive analysis of 90 patients in a single center.","authors":"Mehmet Oğuzhan Özyurtkan, Zeliha Arslan Ulukan, Uğur Temel","doi":"10.5606/tgkdc.dergisi.2024.25655","DOIUrl":"10.5606/tgkdc.dergisi.2024.25655","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate clinical and radiological characteristics of the patients with cough-induced rib fractures.</p><p><strong>Methods: </strong>Between January 2008 and December 2022, a total of 90 patients (35 males, 55 females; mean age: 58±20 years; range, 20 to 92 years) who had cough-induced rib fractures were retrospectively analyzed. Patients' characteristics, findings of physical and radiological examination, and patients' outcomes were recorded.</p><p><strong>Results: </strong>Of the patients, 64% were postmenopausal, 37% had metabolic disease of the bone, and 21% had chronic cough. Cough etiology was acute upper respiratory tract infection (32%), followed by chronic obstructive pulmonary disease. Thoracic computed tomography documented 154 fractures. Cough-induced rib fractures were mostly on the right side (58%). Multiple fractures were more commonly seen in older patients (p=0.007), in the presence of novel coronavirus disease-2019 (COVID-19) pneumonia (p=0.03), and metabolic disease of the bone (p=0.01). Mostly the sixth rib was affected (23%). Most fractures (81.3%) affected the fourth to ninth ribs. Most fractures developed on the anterolateral aspect of the rib (51%). The mean duration of hospital stay was 5.0±1.6 days. Morbidity developed in one patient (1.1%) (hemothorax). Mortality occurred in two patients (2.2%) due to COVID-19 pneumonia and acute myocardial infarction.</p><p><strong>Conclusion: </strong>Localized pain after cough should be investigated in terms of cough-induced rib fractures. Cough-induced rib fractures are mostly seen in the presence of acute upper respiratory tract infection, chronic obstructive pulmonary disease, and pneumonia. Postmenopausal women are more risky to develop cough-induced rib fractures. Multiple cough-induced rib fractures are common in the presence of metabolic disease of the bone, older age, COVID-19 pneumonia.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 1","pages":"69-74"},"PeriodicalIF":0.6,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1